Stay updated on Bispecific Antibody MCLA-158 Clinical Trial
Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page
- ChecktodayChange DetectedMerus N.V. was removed and Merus B.V. was added as the sponsor. The page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedGlossary toggle controls were added (Show glossary, Hide glossary) and new metadata items Last Update Submitted that Met QC Criteria and No FEAR Act Data were introduced, along with a revision note Revision: v3.4.0. The older variants Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.2%

- Check23 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page's Locations section was updated to include a consolidated list of states. Individual state location pages were removed, and the revision updated to v3.3.3.SummaryDifference0.8%

- Check72 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed, reflecting a page version metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedRemoved the government funding lapse notice; the study details content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.